Biogen Inc. (BIIB)
NASDAQ: BIIB · Real-Time Price · USD
140.98
+0.43 (0.31%)
At close: Jan 21, 2025, 4:00 PM
141.55
+0.57 (0.40%)
After-hours: Jan 21, 2025, 6:47 PM EST
Biogen Revenue
Biogen had revenue of $2.47B in the quarter ending September 30, 2024, a decrease of -2.55%. This brings the company's revenue in the last twelve months to $9.61B, down -3.86% year-over-year. In the year 2023, Biogen had annual revenue of $9.84B, down -3.32%.
Revenue (ttm)
$9.61B
Revenue Growth
-3.86%
P/S Ratio
2.13
Revenue / Employee
$1,269,155
Employees
7,570
Market Cap
20.54B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 9.84B | -337.80M | -3.32% |
| Dec 31, 2022 | 10.17B | -808.30M | -7.36% |
| Dec 31, 2021 | 10.98B | -2.46B | -18.32% |
| Dec 31, 2020 | 13.44B | -933.30M | -6.49% |
| Dec 31, 2019 | 14.38B | 925.00M | 6.88% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 400.28B |
| Johnson & Johnson | 87.70B |
| Merck & Co. | 63.17B |
| AbbVie | 55.53B |
| AstraZeneca | 51.21B |
| Novartis AG | 49.94B |
| Thermo Fisher Scientific | 42.37B |
| Abbott Laboratories | 41.22B |
BIIB News
- 6 days ago - Biogen Inc. (BIIB) J.P. Morgan 43rd Annual Healthcare Conference (Transcript) - Seeking Alpha
- 7 days ago - Biogen CEO sees no burning need for more acquisitions - Reuters
- 8 days ago - FDA Accepts LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease - GlobeNewsWire
- 8 days ago - Sage Therapeutics Stock Soars as Biogen Makes Unsolicited Takeover Bid - Investopedia
- 8 days ago - Sage Therapeutics Stock Rockets 35% Higher After Takeover Bid From Biogen - Barrons
- 11 days ago - Sage Therapeutics Confirms Receipt of Unsolicited Nonbinding Acquisition Proposal from Biogen - Business Wire
- 11 days ago - Biogen proposes to buy remaining stake in Sage in $442 million deal - Reuters
- 13 days ago - Cardurion Pharmaceuticals Appoints Charlotte Newman as Chief Business Officer - Business Wire